AACR-NCI-EORTC to Hold Molecular Targets Meeting in San FranciscoNovember 10, 2011SAN FRANCISCO Progress in oncology drug development will take center stage Nov. 12-16, 2011, as thousands of scientists and industry experts convene at the Mos...
HDAC Inhibitor May Overcome Resistance to Common Breast Cancer DrugNovember 13, 2011 HDAC inhibitor with tamoxifen treatment reduced tumor cell resistance in estrogen receptor-positive breast cancer.Critical pathway by which tumors become ta...
Some Tumors Contain Factors that May Block MetastasisNovember 14, 2011 Concomitant tumor resistance to metastasis seen in laboratory models. Cancer-associated forms of the amino acid tyrosine act as anti-metastasis factors.Process might be m...
AACR Calls for Letters of Intent for a Stand Up To Cancer-Prostate Cancer Foundation Dream TeamOctober 25, 2011PHILADELPHIA Stand Up To Cancer (SU2C) and the Prostate Cancer Foundation (PCF), along with the American Association for Cancer Re...
AACR Urges Congress to Safeguard Funding for FDA, Cites 35 Drug Approvals in 2011 as Validation of Agency's EffectivenessNovember 10, 2011SAN FRANCISCO Underscoring the importance of a fully funded U.S. Food and Drug Administration in advanc...
Combination Therapy Shows Potent Tumor Growth Inhibition in Preclinical StudiesNovember 13, 2011 VEGF and Ang2 are critical factors required for tumor angiogenesis.Combined blockade of VEGF and Ang2 with investigational agents enhances antit...
Benefit of Novel Drug in Breast Cancer Seen in Blood Within Weeks November 13, 2011 HDAC inhibitor first to show benefit in a controlled study in breast cancer. Protein lysine acetylation linked to longer disease-free survival. Study shows c...
Thirteen AACR Members Elected to the Institute of MedicineOctober 25, 2011PHILADELPHIA The American Association for Cancer Research congratulates 13 of its members who are among 65 new members and five foreign associates elected to the Insti...
Novel Monoclonal Antibody Offers Potential Treatment for Tumors Resistant to VEGF TherapyNovember 13, 2011 Shutting down the ALK-1 receptor inhibits the VEGF pathway.Response seen in patients who had used antiangiogenic therapy.VEGF therapie...
HDAC Inhibitor May Overcome Resistance to Common Breast Cancer DrugNovember 13, 2011 HDAC inhibitor with tamoxifen treatment reduced tumor cell resistance in estrogen receptor-positive breast cancer.Critical pathway by which tumors become ta...
